| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ... The lancet oncology 6 (5), 279-286, 2005 | 1169 | 2005 |
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 942 | 2016 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 769 | 2017 |
| Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer A Sartore-Bianchi, F Di Nicolantonio, M Nichelatti, F Molinari, S De Dosso, ... PloS one 4 (10), e7287, 2009 | 320 | 2009 |
| Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ... Journal of the National Cancer Institute 108 (1), djv306, 2016 | 150 | 2016 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019 | 131 | 2019 |
| HER2 positivity predicts unresponsiveness to EGFR‐targeted treatment in metastatic colorectal cancer A Sartore‐Bianchi, A Amatu, L Porcu, S Ghezzi, S Lonardi, F Leone, ... The oncologist 24 (10), 1395-1402, 2019 | 123 | 2019 |
| Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer A Amatu, A Somaschini, G Cerea, R Bosotti, E Valtorta, P Buonandi, ... British journal of cancer 113 (12), 1730-1734, 2015 | 80 | 2015 |
| Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer F Tosi, A Sartore-Bianchi, S Lonardi, A Amatu, F Leone, S Ghezzi, ... Clinical colorectal cancer 19 (4), 256-262. e2, 2020 | 68 | 2020 |
| Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. FG De Braud, L Pilla, M Niger, S Damian, B Bardazza, A Martinetti, ... Journal of Clinical Oncology 32 (15_suppl), 2502-2502, 2014 | 50 | 2014 |
| Alka-372-001: First-in-human, phase I study of entrectinib–an oral pan-trk, ROS1, and ALK inhibitor–in patients with advanced solid tumors with relevant molecular alterations. FG De Braud, M Niger, S Damian, B Bardazza, A Martinetti, G Pelosi, ... Journal of Clinical Oncology 33 (15_suppl), 2517-2517, 2015 | 47 | 2015 |
| Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer A Amatu, L Barault, C Moutinho, A Cassingena, K Bencardino, S Ghezzi, ... Annals of Oncology 27 (6), 1062-1067, 2016 | 39 | 2016 |
| Entrectinib for the treatment of metastatic NSCLC: safety and efficacy A Sartore-Bianchi, EG Pizzutilo, G Marrapese, F Tosi, G Cerea, S Siena Expert Review of Anticancer Therapy 20 (5), 333-341, 2020 | 31 | 2020 |
| Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within phase I/II clinical studies based on individual biomarkers of … A Sartore-Bianchi, A Amatu, E Bonazzina, S Stabile, L Giannetta, G Cerea, ... Targeted Oncology 12, 525-533, 2017 | 16 | 2017 |
| TRKA expression and NTRK1 gene copy number across solid tumours G Mauri, E Valtorta, G Cerea, A Amatu, M Schirru, G Marrapese, V Fiorillo, ... Journal of Clinical Pathology 71 (10), 926-931, 2018 | 15 | 2018 |
| RXDX-101, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations FGM De Braud, L Pilla, M Niger, S Damian, B Bardazza, A Martinetti, ... Annals of Oncology 25, iv148, 2014 | 14 | 2014 |
| Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label … S Pignata, G Scambia, C Schettino, L Arenare, C Pisano, D Lombardi, ... The Lancet Oncology 24 (3), 286-296, 2023 | 8 | 2023 |
| Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues S Siena, M Moroni, G Marrapese, A Sartore-Bianchi, S Veronese, ... US Patent App. 11/911,380, 2009 | 7 | 2009 |
| Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer A Sartore-Bianchi, G Cerea, I Schiavetto, L Giannetta, R Ricotta, ... Annals of oncology 17, ii49-ii51, 2006 | 7 | 2006 |
| First-line single-agent cetuximab in patients with advanced colorectal cancer A Pessino, S Artale, A Guglielmi, S Sciallero, G Fornarini, IC Andreotti, ... Journal of Clinical Oncology 24 (18_suppl), 3553-3553, 2006 | 6 | 2006 |
